The use of targeted panel sequencing has helped identify multiple hotspot activating alterations in EGFR-mutant cancers, most notably missense mutations in EGFR at amino acids A289, G719, and L858, although activating alterations in EGFR can also include in-frame insertions and deletions, truncations, fusions, and amplifications6–8. The gene discussed is EGFR; the disease is cancer.